Qualitative and quantitative research of medication review and drug-related problems in Hungarian community pharmacies: a pilot study by Szilvay András et al.
RESEARCH ARTICLE Open Access
Qualitative and quantitative research of
medication review and drug-related
problems in Hungarian community
pharmacies: a pilot study
András Szilvay, Orsolya Somogyi, Attiláné Meskó, Romána Zelkó and Balázs Hankó*
Abstract
Background: Pharmaceutical care is the pharmacist’s contribution to the care of individuals to optimize medicines
use and improve health outcomes. The primary tool of pharmaceutical care is medication review. Defining and
classifying Drug-Related Problems (DRPs) is an essential pillar of the medication review. Our objectives were to
perform a pilot of medication review in Hungarian community pharmacies, a DRP classification was applied for the
first time. Also, our goal was the qualitative and quantitative description of the discovered DRPs, and of the
interventions for their solution in order to prove the safety relevance of the service and to map out the
competence limits of GPs and community pharmacists to drug therapy.
Methods: The project took place in Hungarian community pharmacies. The study was performed with patients
taking vitamin K antagonist (VKA) and/or ACE inhibitor and NSAID simultaneously (ACEI-NSAID). 61 pharmacists and
606 patients participated in the project. Pharmacists reviewed the medication for 3 months and the classification of
DRPs was performed (category of DRP1 – DRP6). Patient data were statistically analyzed.
Results: Patients consumed on average 7.9 ± 3.1 medications and other products. 571 DRPs were detected in 540
patients, averaging 1.06 DRPs per patient (SD = 1.07). The highest frequency category was DRP5 (non-quantitative
safety problem; 51.0%). The most common root cause was an interaction (42.0%) and non-adherence (19.4%.). The
most commonly used intervention was education (25.4%) and medication replacement by the pharmacist (20.1%).
The changing of the frequency and dosage in any direction were negligible.
Conclusions: Patients are struggling with many DRPs that can be assessed and categorized by this system and
which remain unrecognizable without pharmacists. Further projects need to be developed to assist in the
development of physician-pharmacist cooperation and the widespread dissemination of pharmaceutical care.
Keywords: Drug-related problem, Medication review, Pharmaceutical care, Community pharmacy, Vitamin K
antagonist, ACE inhibitor
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Background
According to the definition of Pharmaceutical Care Net-
work Europe “Pharmaceutical Care is the pharmacist’s
contribution to the care of individuals to optimize medi-
cines use and improve health outcomes”. [1] The goal of
the pharmacists is to collect the patient’s medications
(Rx, OTC) and other products (e.g. dietary supplements)
to ensure their necessity, efficacy and safety. [2]
The main tool of pharmaceutical care is medica-
tion review, “a structured, critical examination of a
patient’s medicines with the objective of reaching an
agreement with the patient about treatment, optimiz-
ing the impact of medicines, minimizing the number
of medication-related problems and reducing waste”.
[3] The best way to make medication review is in
collaboration with the patients and their general
practitioners. [4, 5] To demonstrate the benefits of
medication review, several but controversial articles
have published. It reduces the number of cases re-
quiring emergency care [6, 7], the number of (re)
hospitalizations, but its beneficial effects on quality
of life, adverse drug reactions and mortality are
non-significant in high-risk groups. [7, 8] However
according to other articles it reduces the number of
(unnecessary) drugs [9–12], it helps to detect and
solve drug-related problems (DRPs) [9, 13–17], espe-
cially in collaboration with hospital pharmacists [18],
it increases the patients’ trust in the therapy [19]
and the cost-effectiveness of the treatment [20].
Defining and classifying drug-related problems is an
essential pillar of the medication review. The
drug-related problems are “situations in which in the
process of use of medicines cause or may cause the
appearance of a negative outcome associated with the
medication.” [21] There are many reasons for the
drug-related problems, which may result that drug
therapy is not achieving its purpose or even becoming
harmful. There are more than 20 types of DRP classi-
fication system in the literature, which differ in, e.g.
DRP groups and methodology. [22] It is also import-
ant to involve patients in the process of detecting
drug-related problems. [23]
The aim of our research was to perform a pilot of medi-
cation review in Hungarian community pharmacies as part
of basic pharmaceutical care, using a drug-related problem
classification for the first time to lay the foundation for
wider adoption of this service in Hungary. Also, our goal
was the qualitative and quantitative description of the dis-
covered drug-related problems, and of the interventions for
their solution in order to prove the safety relevance of the
service and to map out the competence limits of GPs and
community pharmacists to drug therapy. The latter can
contribute to the development of a future “target model” of
doctor-patient-pharmacist cooperation.
Methods
Description of the project
The project took place between December 2015 and
August 2016. The data were collected by pharmacists
(they have not received monetary compensation) partici-
pating in specialist training at Semmelweis University. The
participation of pharmacists was obligatory to complete
the second year of the training, and the cooperative
pharmacies were their own workplaces. All participating
pharmacies were accredited at the Semmelweis Univer-
sity. All the participating pharmacists from all around the
country went to Budapest and participated in one-day
training at Semmelweis University, which included the
description and requirements of the project, and the
presentation of the drug-related problem classification.
The pharmacists at the beginning of the project visited
family practitioners working near the pharmacy, practic-
ally those whose patients often go to the pharmacy. They
were invited to participate in the project. After that, the
patients were involved in the pharmacy. The study was
performed with patients taking vitamin K antagonist
(VKA) and/or ACE inhibitor and NSAID simultaneously
(ACEI-NSAID). The latter is considered as a high-risk
group because of the increased chance of renal failure
[24] and the potential inadequacy of the therapy [25]. A
patient could have been in both categories. Patients had
to be at least 18 years old, had to buy medicines
themselves and had to be the patients of the general
practitioner involved. All pharmacists tried to have
around 10 patients. The process of the first and further
occasions is described in Fig. 1.
Characteristics of participating pharmacies and patients
Data for patients and pharmacies in the study are shown
in Table 1. 61 pharmacists took part in 61 pharmacies.
The survey was close to nationwide coverage (16 of 20
counties). Most of the pharmacies were in the capital
(35.6%). 606 patients participated in the project (9.9 pa-
tients/pharmacy; SD = 3.0), 57.3% were women and
42.7% were males. 497 patients (mean = 8.1; SD = 2.2)
took part in every requested meeting with the pharma-
cist (traced patients), 18.0% of the patients left the pro-
ject. However, we used data from all the patients
involved, not only from traced patients. The average age
of patients was 65.0 years (SD = 11.9). 55.6% of the par-
ticipants took ACE inhibitor and NSAID simultaneously,
39.8% of them took vitamin K antagonists, and 4.6% of
them were included in both categories.
Medication review
Pharmacists have been conducting medication review at
each consultation; they looked at medication taken from
the point of necessity, effectiveness and safety. The
medication review and the classification of drug-related
Szilvay et al. BMC Health Services Research          (2019) 19:282 Page 2 of 10
Fig. 1 The process of the occasions
Table 1 Data for patients and pharmacists involved in the study (SD = standard deviation)
∑ MEAN ± SD Number of pharmacists involved: 61
Number of patients involved: 606 9.9 ± 3.0
Traced patients: 497 8.1 ± 2.2 Number of pharmacies involved: 61
Dropout rate: 18.0%
Location of pharmacies (n = 59)
Sex (n = 514) Capital city: 35.6%
Male: 42.7% County towns: 15.3%
Female: 57.3% Other cities: 33.9%
Other: 15.2%
Age of patients (n = 540)
Mean ± SD (year) 65.0 ± 11.9 Distribution of patients (n = 526)
Range: 24–96 year Capital city: 34.0%
< 65 years: 50.6% County towns: 15.2%
≥ 65 years: 49.4% Other cities: 35.8%
Other: 15.0%
Patient group (n = 540)
ACEI-NSAID: 55.6% Products (n = 540) MEAN ± SD
VKA: 39.8% Number of products: 7.9 ± 3.1
Both: 4.6% Prescription drug: 6.3 ± 2.8
OTC: 1.1 ± 1.1
Other: 0.4 ± 0.8
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problems were performed according to the Third Con-
sensus of Granada on Drug-Related Problems classifica-
tion system [21] and to the Hungarian National
Committee of Pharmaceutical Care Metabolic Syndrome
Pharmaceutical Care Programme. [26] In the process of
assessing drug-related problems, the pharmacist classi-
fied the DRPs into six classes and identified the root
cause. (Table 2).
The number and cause of the drug-related problem
were recorded by the pharmacist. In addition, the inter-
vention was also recorded. The medication review was
performed at all pharmacist meetings. Anonymous pa-
tient data were statistically analyzed.
Statistical analysis
Statistical calculations were performed using SPSS 20.0.
After the descriptive statistical analysis, two sample t
test, paired sample t test, and a variance analysis were
performed on continuous data to detect differences and
correlations. When calculating the Pearson correlation
coefficient, the p value for the correlation coefficient was
< 0.005. For discrete data, the Kruskal-Wallis test and
chi-square test were used. Control of normality was
performed with Kolmogorov Smirnov test. The signifi-
cance level was p = 0.05.
Ethics approval and consent to participate
The project was implemented with the support and co-
operation of the National Health Development Institute’s
Primary Care Directorate [27]. The unified professional
protocol made available in the course of the
co-operation is a document agreed with the Primary Ser-
vice Directorate. We have not received a waiver of ethics
approval since the participation in the questionnaire sur-
vey, and the pharmaceutical service was not linked to
one Institute (University) and was absolutely free and
undoubtedly noninvasive, so IRB deemed unnecessary
according to the similar national regulations. In Hungary
according to Regulation No 44/2004 MoHSFA and Act
XLVII of 1997, pharmacies did not need to be individu-
ally ethically licensed, because the service complies with
statutory regulations, and pharmacies are legally entitled
to perform such activities [28–31]. Verbal informed con-
sent was obtained from all participants in the pharma-
cies; no written consent was required according to the
Act CLIV of 1997 on Health (noninvasive pharmaceut-
ical service and questionnaire survey) [32].
Table 2 DRP classification and their underlying cause. [21, 26]
Drug-related problem Underlying cause
Necessity DRP1 Untreated health problem.
The patient suffers from a
health problem as a consequence
of not receiving the medicine
that he/she needs.
Medication is necessary
(lack of the required
medication)
DRP2 Effect of unnecessary medicine.
The patient suffers from a health
problem as a consequence of
receiving the
medicine that he/she does
not need.
Unnecessary taken drug
Multiple drug use from
the same pharmacological
category
Effectiveness DRP3 Non-quantitative ineffectiveness.
The patient suffers from a health
problem associated with a
non-quantitative ineffectiveness
of the medication.
Improper medication
choice
Non-adherence
DRP4 Quantitative ineffectiveness.
The patient suffers from a
health problem associated
with a quantitative ineffectiveness
of the medication.
Improper dosage
Safety DRP5 Non-quantitative safety problem.
The patient suffers from a health
problem associated with a
non-quantitative safety
problem of the medication.
Interaction
Side effects
DRP6 Quantitative safety problem.
The patient suffers from a health
problem associated with a
quantitative safety problem
of the medication
Improper dosage
Other
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The investigation was a free service of pharmacies with
operating licenses. The patients involved voluntarily par-
ticipated in the process. Patients participating in the pro-
ject received verbal information in accordance with the
national regulations mentioned above. Qualified phar-
macists conducted the project. The data were handled
by pharmacy and health data management according to
Act XLVII of 1997. Data were transmitted without per-
sonal information to process the results. The personal
and health data of the patients included in the study
were not damaged.
Results
Descriptive results
In the assessment of drug-related problems, 540 patients
from 606 patients were collected and analyzed. On aver-
age, patients consumed 7.9 ± 3.1 medications and other
products: 6.3 were prescription drug (SD = 2.8), 1.1 OTC
(SD = 1.1) and 0.4 other product, for example dietary sup-
plements (SD = 0.8). (Table 1).
During the study, 571 drug-related problems were
detected in these 540 patients, averaging 1.06 DRP
per patient (SD = 1.07). The highest frequency
category was DRP5 (non-quantitative safety problem:
51.0%). Approximately one-fourth of cases (24.0%)
belonged to DRP3 (non-quantitative ineffectiveness)
and 10% to DRP1 (untreated health problem). DRP2
(Effect of unnecessary medicine), DRP4 (Quantitative
ineffectiveness) and DRP6 (Quantitative safety prob-
lem) were less frequent (8.2, 4.6, 2.3%). (Fig. 2-All
patients).
Analyzing the root causes of drug-related prob-
lems, the most common was the interaction (42.0%),
the second was non-adherence (19.4%). The Quanti-
tative safety problem caused by improper dosage was
the rarest (2.3%). (Fig. 3-All patients).
In the case of ACEI-NSAID patients, the DRP1
category appears to be higher (13.9%) than in the
case of VKA patients (4.7%). The ratio was reversed
in the case of DRP3 (22.1 and 27.8%) and DRP5
(48.2% or 52.4%), the latter is due to a higher rate of
interactions. (Figs. 2 and 3) The ratio of interaction
was extremely high for those patients who were in
both categories (65.5%). (Fig. 3) However, these dif-
ferences are not significant either in the number of
drug problems or in the occurrence of the individual
Fig. 2 The relative proportion of different drug-related problem categories per patient group (All patients: all the participating patients (n = 571);
ACEI-NSAID: patients taking ACE inhibitor and NSAID simultaneously (n = 330); VKA: patients taking vitamin K antagonist (n = 212); Both: patients
included in both categories (n = 29); DRP: drug-related problem (see Table 2))
Szilvay et al. BMC Health Services Research          (2019) 19:282 Page 5 of 10
categories and causes. There was no “other” problem
that cannot be categorized elsewhere.
Results of statistical analysis
There are no differences in the prevalence of drug-related
problems between men and women (p = 0.070) and be-
tween the patients over and under 65 years. (p = 0.552).
There is a significant difference between the types of
settlement in the occurrence of the drug-related prob-
lem. In the capital city, the pharmacists have found two
DRPs per patient in a significantly higher ratio, while in
other settlements it was markedly higher that the
pharmacist found no mistake in the medication. There is a
correlation between the number of DRPs and the total
number of used medications, but the correlation is weak
(Pearson correlation coefficient = 0.214 (p < 0.005)). The re-
lationship between the number of prescription drugs and
the number of drug-related problems is similar, somewhat
lower (Pearson correlation coefficient = 0.152 (p < 0.005)).
Table 3 summarizes the rates of interventions used to
eliminate drug-related problems. The most common
intervention for the elimination of each underlying cause
was indicated with bold number, while underlined num-
ber indicates the interventions with an incidence higher
Fig. 3 The relative proportion of the underlying cause of drug-related problems per patient group (All patients: all the participating patients (n = 571);
ACEI-NSAID: patients taking ACE inhibitor and NSAID simultaneously (n = 330); VKA: patients taking vitamin K antagonist (n = 212); Both: patients
included in both categories (n = 29); DRP: drug-related problem (see Table 2))
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than 10%. Overall, the most commonly used intervention
was education (25.4%) and medication replacement by the
pharmacist (20.1%). More than 10% of the problems the
intervention was not necessary (10.9%), or the pharmacist
sends the patient to a physician (14.5%) or the pharmacist
warned the GP (11.7%). The changing of the frequency
and dosage in any direction were negligible.
Discussion
Due to a large number of patients involved and the low
drop-out rate, patients are interested and find the service
provided by pharmacists useful. The fact that a large
number of patients who had NSAIDs with an ACE in-
hibitor were included in the study underlined the rele-
vance of this problem. Such a problem frequently does
not show up at the doctor but at the pharmacy. The pro-
ject involved a large number of patients with more than
5 medicines (also known as polypharmacy patients [33]).
It is noteworthy that patients use an average of 1 OTC
drug on a regular basis, and that 4 out of 10 patients also
use some other formulations (e.g. dietary supplements).
The use of these two product categories can only be
supervised by the pharmacist. The patient’s medication
is fully matched at expedition at the pharmacy only (Rx,
OTC, other products) so the pharmacy service presented
in the project plays an essential role in the assessment and
resolution of drug-related problems. It is supported by a
large number of DRPs that have been identified and classi-
fied in this project based on a drug-related problem classi-
fication system that has been used for the first time in
Hungary. In addition to the reasons mentioned above, the
overload of general practitioner services can also contrib-
ute. Among the DRP categories, there is a high amount of
non-quantitative safety problems in all patient groups,
which are mainly drug-drug or drug-other product inter-
actions. The latter is also influenced by the patient’s in-
volvement in the ACEI-NSAID group. However, we
cannot talk about such a factor in the VKA group. This
phenomenon is due to the uncontrolled use of the vast
amounts of prescription and OTC medicines mentioned
earlier and the other medicines are taken by 4 out of 10
patients. The problem may be solved by pharmacists who
have resolved the situation in our research with education,
medication replacement (especially OTC-OTC drug
switching) and by sending the patient to the GP. In the
case of interactions, “stop medication” has hardly oc-
curred, and pharmacists seem to be hesitant to take this
step, as they think that the physician is the one who com-
petent to make this decision. Another major problem is
the Non-quantitative ineffectiveness of the medication of
a quarter of patients due primarily to their deliberate or
unintended non-adherence.
Non-adherence is a widespread problem with chronic
diseases for example in the case of conditions treated with
ACE inhibitor and vitamin K antagonist. The pharmacist
can help by detecting the problem and education. It is also
important to mention that every tenth ACEI-NSAID pa-
tient is suffering from an untreated health problem. The
research has shown that in many cases the pharmacist has
noticed such a health problem, which has been solved by
drug recommendation and by sending the patient to the
GP. Based on these results, a medication review in the
framework of basic pharmaceutical care can be a solution
beyond the problems mentioned above in preventing the
risks of self-medication.
In the case of medication review, it is also necessary to
address the issue of competency conflict between the
pharmacist and the general practitioner. By looking at the
pharmacists’ interventions to resolve drug-related prob-
lems, we can see that 59.7% of the problems have been
solved by the pharmacist without the involvement of a
physician, primarily through education and the exchange of
a patient’s drug with an OTC drug. The pharmacist in his/
her own solved only about 5–6% of the cases by recom-
mending a new drug or stopping a therapy, while the chan-
ging of frequency and dosage were as rare as possible
without consultation with the physician. Pharmacists sent
patients more to the physician without indicating the prob-
lem being diagnosed to them. Pharmacists preferred to
send patients to doctors without consulting the GP, sug-
gesting low levels of co-operation between two professions
and pharmacists’ fears of doctors. Analyzing the effect of
certain population factors on drug-related problems, it can
be stated that among the examined factors, the number of
DRPs is only influenced by the geographical location of the
pharmacies. This, assuming that patients seek indirectly the
pharmacy closest to their home first, refers indirectly to the
influence of the type of residential township. Based on the
results, it is assumed that a more extensive settlement poses
a higher risk for patients, due to the less personal
physician-patient and pharmacist-patient relationship, the
more likely to be accessed by more accessible medical ser-
vices. So the development of a regular pharmacist-patient
relationship is of the utmost importance in this area.
Conclusion
Based on the results of the 540 patients surveyed in the 61
Hungarian pharmacies we can conclude that patients are
struggling with many drug-related problems that can be
assessed and categorized by this system and which remain
unrecognizable without pharmacists. To achieve this, fur-
ther projects need to be developed to assist in the devel-
opment of physician-pharmacist cooperation and the
widespread dissemination of pharmaceutical care. Our re-
sults provide a reasonable basis for the widespread use of
medication review. In the future, it would be worthwhile
extending the study to other patient groups, such as eld-
erly patients with polypharmacy.
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